Details for Patent: 12,083,112
✉ Email this page to a colleague
Which drugs does patent 12,083,112 protect, and when does it expire?
Patent 12,083,112 protects LENVIMA and is included in one NDA.
This patent has thirteen patent family members in five countries.
Summary for Patent: 12,083,112
| Title: | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| Abstract: | The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I):wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody. |
| Inventor(s): | Andrew Evan DENKER, Yu Kato, Kimiyo Tabata, Yusaku Hori |
| Assignee: | Eisai R&D Management Co Ltd, Merck Sharp and Dohme LLC |
| Application Number: | US17/502,962 |
|
Patent Claim Types: see list of patent claims |
More… ↓ |
Drugs Protected by US Patent 12,083,112
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | FIRST-LINE TREATMENT OF ADULTS PATIENTS WITH ADVANCED RENAL CELL CARCINOMA BY ADMINISTERING LENVIMA IN COMBINATION WITH PEMBROLIZUMAB | ⤷ Subscribe | ||||
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF PATIENTS WITH PMMR/NOT MSI-H ADVANCED ENDOMETRIAL CARCINOMA, HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY, AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION, BY ADMINISTERING LENVIMA IN COMBINATION WITH PEMBROLIZUMAB | ⤷ Subscribe | ||||
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | FIRST-LINE TREATMENT OF ADULTS PATIENTS WITH ADVANCED RENAL CELL CARCINOMA BY ADMINISTERING LENVIMA IN COMBINATION WITH PEMBROLIZUMAB | ⤷ Subscribe | ||||
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF PATIENTS WITH PMMR/NOT MSI-H ADVANCED ENDOMETRIAL CARCINOMA, HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY, AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION, BY ADMINISTERING LENVIMA IN COMBINATION WITH PEMBROLIZUMAB | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,083,112
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015384801 | ⤷ Subscribe | |||
| Canada | 2978226 | ⤷ Subscribe | |||
| Japan | 2016196411 | ⤷ Subscribe | |||
| Japan | 2018512391 | ⤷ Subscribe | |||
| Japan | 2021035962 | ⤷ Subscribe | |||
| Japan | 2023039448 | ⤷ Subscribe | |||
| Japan | 6788600 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
